LeMaitre Vascular, Inc. (LMAT) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $91.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Negative momentum.
LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral vascular, renal, and cardiovascular disease, selling primarily through a 160-person direct sales force in North America, Europe, and Asia Pacific. In 2025, ~95% of... Read more
Hold if already holding. Not a fresh buy at $91.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — LeMaitre Vascular, Inc.
Latest news
- NEWS Comerica Bank Lowers Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat — MarketBeat neutral
- NEWS Wells Fargo & Company Forecasts Strong Price Appreciation for LeMaitre Vascular (NASDAQ:LMAT) Stock - MarketBeat — MarketBeat positive
- NEWS LeMaitre Vascular (NASDAQ:LMAT) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat — MarketBeat positive
- NEWS Citizens raises LeMaitre Vascular stock price target on margin outlook By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole- and limited-source suppliers10-K Item 1A: 'We rely on sole- and limited-source suppliers for many of our important components and certain products, including our VascuCel and CardioCel biologic patch, Artegraft biologic vascular graft and Omniflow biosynthetic vascular graft.'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02LOWBridget Ross notified LeMaitre Vascular's Board on April 8, 2026 of her intent not to stand for re-election as a Class II director at the June 2, 2026 Annual Meeting. Her decision is not related to any disagreement with the Company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $91.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $103.31 (+12.3%), stop $87.57 (−5.0%), A.R:R 1.9:1. Score 5.7/10, moderate confidence.
Take-profit target: $103.31 (+12.3% upside). Target $103.31 (+12.3%), stop $87.57 (−5.0%), A.R:R 1.9:1. Stop-loss: $87.57.
Concentration risk — Supplier: sole- and limited-source suppliers; Negative momentum.
LeMaitre Vascular, Inc. trades at a P/E of 33.8 (forward 28.2). TrendMatrix value score: 4.0/10. Verdict: Hold.
15 analysts cover LMAT with a consensus score of 4.0/5. Average price target: $119.
What does LeMaitre Vascular, Inc. do?LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral...
LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral vascular, renal, and cardiovascular disease, selling primarily through a 160-person direct sales force in North America, Europe, and Asia Pacific. In 2025, ~95% of net sales were generated through direct-to-hospital channels and 43% were international; no single hospital customer exceeded 2% of net sales.